Development of SIVEXTRO; A New Oxazolidinone Antibiotics

조회수 : 378 등록일 : 2016.11.23 15:57

일시 : 2016.11.23 17:00
소속 : 동아ST
발표자 : 임원빈
장소 : AS510
   The oxazolidinones represent a novel chemical class of synthetic antimicrobial agents. Tedizolid is a second generation oxazolidinone antibacterial drug. It is a potent inhibitor of Gram-positive bacterial pathogens such as methicillin-resistant Staphylococccus aureus, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant Enterococcus spp. Tedizolid is also active against pathogens that have developed resistance to first generation oxazolidinones such as linezolid-resistant S. aureus and linezolid-resistant Enterococcus spp. With a long half-life, high bioavailability and solubility and high potency, Tedizolid will provide clinicians with flexible dosing and a possible shorter course of therapy thereby enabling the early transition of hospitalized patients from IV to oral treatment and subsequent early discharge from the hospital. Tedizolid had successfully completed Phase I ,Phase II and Phase III clinical trials. SIVEXTRO(Tedizolid) has been approved by the FDA on June 20, 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria. In this presentation, overall progress of the development of SIVEXTRO will be discussed.
  • 목록보기
  • 이전글보기
  • 다음글보기